# US 11,078,268 B2 · IL-11 antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,078,268 B2
- Document ID: US11078268B2
- Status: Granted
- Kind: B2
- Application number: 16/726,173
- Filed: 2019-12-23
- Published: 2020-06-25
- Granted: 2021-08-03
- Earliest claimed: 2016-12-16
- Assignees: Singapore Health Services Pte Ltd; National University of Singapore
- Applicants: Singapore Health Services PTE LTD.; National University of Singapore
- Inventors: Stuart Alexander Cook; Sebastian Schaefer
- Web page: https://patentgrep.com/patent/US11078268B2

## CPC

- C07K 16/244: {Interleukins [IL]}
- A61K 47/6845: {the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon}
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 27/02: Ophthalmic agents
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/5431: {IL-11}
- C07K 14/7155: {for interleukins [IL]}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/20: characterized by taxonomic origin
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/515: Complete light chain, i.e. VL + CL
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2319/75: containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

IL-11 antibodies are disclosed. Also disclosed are compositions comprising the IL-11 antibodies, and methods using the IL-11 antibodies.

## Claims

### Claim 1

An antibody or antigen binding fragment, which is capable of binding to IL-11, comprising a light chain variable region sequence and a heavy chain variable region sequence, wherein:
the light chain variable region sequence comprises the following CDRs:
i)
LC-CDR1:
(SEQ ID NO: 107)
SSDVGGYNY;
ii)
LC-CDR2:
(SEQ ID NO: 291)
DVN;
and
iii)
LC-CDR3:
(SEQ ID NO: 336)
CSYAGRYTWM;
or a variant comprising 1 amino acid substitution in the sequence CSYAGRYTWM (SEQ ID NO: 336); and
the heavy chain variable region sequence comprises the following CDRs:
i)
HC-CDR1:
(SEQ ID NO: 186)
GFTFSSYG
ii)
HC-CDR2:
(SEQ ID NO: 184)
ISYDGSNK;
and
iii)
HC-CDR3:
(SEQ ID NO: 187)
AKIGATDPLDY.

### Claim 2 (depends on 1)

The antibody or antigen binding fragment according to claim 1, wherein:
the light chain variable region sequence has at least 80% sequence identity to the light chain variable region sequence of SEQ ID NO: 335, and
the heavy chain variable region sequence has at least 80% sequence identity to the heavy chain variable region sequence of SEQ ID NO: 370.

### Claim 3 (depends on 1)

The antibody or antigen binding fragment according to claim 1, wherein the light chain variable region sequence comprises the following CDRs:
i)
LC-CDR1:
(SEQ ID NO: 107)
SSDVGGYNY
ii)
LC-CDR2:
(SEQ ID NO: 291)
DVN;
and
iii)
LC-CDR3:
(SEQ ID NO: 336)
CSYAGRYTWM,
and wherein the heavy chain variable region sequence comprises the following CDRs:
iv)
HC-CDR1:
(SEQ ID NO: 186)
GFTFSSYG;
v)
HC-CDR2:
(SEQ ID NO: 184)
ISYDGSNK;
and
vi)
HC-CDR3:
(SEQ ID NO: 187)
AKIGATDPLDY.

### Claim 4 (depends on 1)

The antibody or antigen binding fragment according to claim 1, which is capable of inhibiting IL-11 trans signalling.

### Claim 5 (depends on 1)

The antibody or antigen binding fragment according claim 1, conjugated to a drug moiety or a detectable moiety.

### Claim 6 (depends on 1)

A method for producing an antibody or antigen binding fragment according to claim 1, comprising culturing a cell comprising a nucleic acid or vector encoding the antibody or antigen binding fragment according to claim 1 under conditions suitable for the expression of the antibody or antigen binding fragment.

### Claim 7 (depends on 6)

The method of claim 6, further comprising isolating the antibody or antigen binding fragment from the cell, thereby producing an isolated antibody or antigen binding fragment.

### Claim 8 (depends on 7)

The method of claim 7, further comprising mixing the isolated antibody or antigen binding fragment with a pharmaceutically acceptable carrier, adjuvant, excipient or diluent.

### Claim 9

A method of treating fibrosis or a disease/disorder characterised by fibrosis, comprising administering an antibody or antigen binding fragment to a subject suffering from fibrosis or a disease/disorder characterised by fibrosis, wherein the antibody or antigen binding fragment is capable of binding to IL-11, and comprises a light chain variable region sequence and a heavy chain variable region sequence, wherein:
the light chain variable region sequence comprises the following CDRs:
i)
LC-CDR1:
(SEQ ID NO: 107)
SSDVGGYNY;
ii)
LC-CDR2:
(SEQ ID NO: 291)
DVN;
and
iii)
LC-CDR3:
(SEQ ID NO: 336)
CSYAGRYTWM;
or a variant comprising 1 amino acid substitution in the sequence CSYAGRYTWM (SEQ ID NO: 336); and
the heavy chain variable region sequence comprises the following CDRs:
i)
HC-CDR1:
(SEQ ID NO: 186)
GFTFSSYG
ii)
HC-CDR2:
(SEQ ID NO: 184)
ISYDGSNK;
and
iii)
HC-CDR3:
(SEQ ID NO: 187)
AKIGATDPLDY.

### Claim 10 (depends on 9)

The method according to claim 9, wherein:
the light chain variable region sequence has at least 80% sequence identity to the light chain variable region sequence of SEQ ID NO: 335, and
the heavy chain variable region sequence has at least 80% sequence identity to the heavy chain variable region sequence of SEQ ID NO: 370.

### Claim 11 (depends on 9)

The method according to claim 9, wherein the light chain variable region sequence comprises the following CDRs:
i)
LC-CDR1:
(SEQ ID NO: 107)
SSDVGGYNY
ii)
LC-CDR2:
(SEQ ID NO: 291)
DVN;
and
iii)
LC-CDR3:
(SEQ ID NO: 336)
CSYAGRYTWM,
and wherein the heavy chain variable region sequence comprises the following CDRs:
i)
HC-CDR1:
(SEQ ID NO: 186)
GFTFSSYG
ii)
HC-CDR2:
(SEQ ID NO: 184)
ISYDGSNK;
and
iii)
HC-CDR3:
(SEQ ID NO: 187)
AKIGATDPLDY.